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Idiopathic basal ganglia calcification (IBGC), also known as Fahr disease or primary familial brain calcifications
(PFBC), is a rare neurodegenerative disorder characterized by calcium deposits in basal ganglia and other brain
regions, causing neuropsychiatric and motor symptoms. We established human induced pluripotent stem cells
(iPSCs) from an IBGC patient. The established IBGC-iPSCs carried SLC20A2 c.1848GNA mutation (p.W616* of
translated protein PiT2), and also showed typical iPSC morphology, pluripotency markers, normal karyotype,
and the ability of in vitro differentiation into three-germ layers. The iPSC linewill be useful for further elucidating
the pathomechanism and/or drug development for IBGC.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Type of cell line iPSC
Origin Human
Additional origin info 28 year-old, male
Cell source Peripheral blood mononuclear cells (PBMCs)
Method of
reprogramming
Episomal vectors (SOX2, KLF4, OCT4, L-MYC, LIN28 and
p53 carboxy-terminal dominant-negative fragment)

















RIKEN BioResource Center, Japan
http://en.brc.riken.jp/index.shtml
Ethical approval Ethics Committee of the Department of Medicine and
Graduate School of Medicine, Kyoto University (approved
No. R0091 and G259), and Gifu university (approved No.
25-65)
Resource utility
IBGC is a rare disease, characterized by massive calcification around
brain vessels and various neurological symptoms, the mechanism of
which is unknown. IBGC-iPSC will provide endothelial cells or neural
cells and help the elucidation of the pathomechanism in the
neurovascular system, one of key targets to treat neurological disorders.
Resource details
Idiopathic basal ganglia calcification (IBGC) is a rare genetic condition
characterized by symmetric calcification in the basal ganglia and other
brain regions. The clinical symptoms of IBGC include neuropsychiatric
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symptoms, dementia, psychosis, seizures, or chronic headache, and nor-
mal serum levels of calcium, phosphate, alkaline phosphatase and para-
thyroid hormone. Typical age at clinical onset is between 20 and
50 years, and most individuals are asymptomatic (Nicolas et al., 2015).
The neuropathological hallmark of IBGC is calcification of peri- and
intra-vascular space of capillaries in the basal ganglia, dentate nuclei of
the cerebellumandwhitematter. IBGC is frequently inherited in an auto-
somal dominantmanner. Approximately half of the cases of familial IBGC
associatewithmutations in SLC20A2, which encodes the type III Na+-de-
pendent inorganic phosphate transporter PiT2 (Yamada et al., 2014). The
mutations are predicted to result in a loss of function of inorganic phos-
phate transport. SLC20A2 knockout mice show cerebrovascular calcifica-
tion. We generated induced pluripotent stem cells (iPSCs) from an IBGC
patient with SLC20A2mutation (c.1848GNA, p.W616* of translated pro-
tein PiT2) Table 1. Established IBGC-iPSCs showed positive staining of
pluripotencymarkers (Fig. 1A). Three germ layer differentiation capacity
was showed in the in vitro differentiation followed by immunohisto-
chemistry staining of the mesodermal marker (alpha smooth muscle
actin: αSMA), the endodermal marker (SOX17), and the ectodermal
marker (βIII-tubulin) (Fig. 1B), Table 2. Established IBGC-iPSCs also
maintained a normal karyotype after reprogramming process (Fig. 1C),
and retained SLC20A2mutation (c.1848GNA, p.W616* of translated pro-




Generation and use of human iPSCs was approved by the Ethics
Committee of theDepartment ofMedicine andGraduate School ofMed-
icine, Kyoto University and Gifu University, and all methods were per-
formed in accordance with the approved guidelines. Formal informed
consent was obtained from the patient.
Establishment of iPSCs
Peripheral blood mononuclear cells (PBMCs) from an IBGC patient
were cultured in StemFit/AK03 A, B without C (Ajinomoto, Tokyo,
Japan) supplemented with IL-6, SCF, TPO, Flt-3L, IL-3, G-CSF (Wako
Pure Chemical Industries, Osaka, Japan). After 7 days of culture,
reprogramming factors, including SOX2, KLF4, OCT4, L-MYC, LIN28
and p53 carboxy-terminal dominant-negative fragment, were trans-
duced into PBMCs with episomal vectors (Okita et al., 2013). PBMCs
were cultivated in disseminated onto MEF feeder-cell with Primate ES
cell medium (ReproCELL Inc., Yokohama, Japan). iPSCs colonies were
picked up, and the iPSC maintenance method was changed to a feed-
er-free system by using StemFit medium (AK02N, Ajinomoto, Tokyo,
Japan) on iMatrix-511 (Nippi, Tokyo, Japan)-coated plates.
Genotyping by sequencing analysis
Genomic DNA was extracted from PBMCs and iPSCs with Purelink
Genomic DNA Kits (Invitrogen, Thermo Fisher Scientific, Waltham,
MA). The SLC20A2 coding region was amplified by using KOD-plus-
Neo (Toyobo, Osaka, Japan) and Veriti Thermal Cycle (Thermo Fisher
Scientific), followed by direct sanger sequence (3700 Genetic Analyzer;
formerly Applied Biosystems, Thermo Fisher Scientific).
In vitro differentiation
The established iPSCs were harvested by TrypLE express (Ther-
mo Fisher Scientific) and cultivated in DMEM/F12/Glutamax (Ther-
mo Fisher Scientific), 20% knockout serum replacement (KSR;
Thermo Fisher Scientific), 10 μM Y-27632(Nacalai tesque, Kyoto,
Japan) on 0.5% Lipidure (Nichiyu, Tokyo, Japan)-coated U-shape-
bottom 96-well-plates (Greiner bio-one, Kremsmünster, Austria)
for generation of aggregates. On day 7, aggregates were seeded
onto matrigel-coated 96-well-plates and differentiated into three-
germ layer in DMEM plus 10% fetal bovine serum (Thermo Fisher
Scientific).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde and blocked with PBST
containing 5% Blocking One Histo (Nacalai tesque, Kyoto, Japan). DAPI
(Thermo Fisher Scientific) was used for nuclei. Fluorescence imaging
was performedbyfluorescencemicroscope BIOREVOBZ-9000 (Keyence,
Osaka, Japan).
Karyotype analysis




Classification Test Result Data
Morphology Photography Similar to human embryonic stem cells Fig. 1 panel A
Phenotype Immunocytochemisty Assess staining of pluripotency markers: NANOG and SSEA-4 Fig. 1 panel A
Flow cytometry SSEA-4 87.6% Fig. 1 panel E
Genotype Karyotype (G-banding) and resolution 46XY, Resolution 450–500 Fig. 1 panel C
Identity Microsatellite PCR (mPCR) Not performed Not performed
STR analysis 16 loci, matched Supplementary Table 1
Mutation analysis (IF
APPLICABLE)
Sequencing Heterozygous, SLC20A2 mutation (c.1848GNA, p.W616* of
translated protein PiT2)
Fig. 1 panel D
Southern Blot OR WGS Not performed Not performed
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence method (MycoAlert™
Mycoplasma Detection Kit).
Negative
Not shown but available
with author
Differentiation potential Embryoid body formation OR Teratoma
formation OR Scorecard
Describe expression of genes in embryod bodies: SOX-17, αSMA,
and βIII-tubulin
Fig. 1 panel B
Donor screening
(OPTIONAL)
HIV 1 + 2 Hepatitis B, Hepatitis C HIV1 (negative), HIV2 (not performed), Hepatitis B (negative),
and Hepatitis C (negative)




Blood group genotyping Not available Not available
HLA tissue typing Not available Not available
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Flow cytometry analysis
iPSCswere dissociated into single cell by using Accumax (Innovative
Cell Technologies, SanDiego, CA), andwere incubated at 1.0×106 cells/-
ml in PBS with 2% FBS and 20 μl SSEA-4 APC conjugatedmonoclonal an-
tibody (BD Biosciences, Franklin Lakes, NJ) for 30 min at 4 °C. After
staining, the cells were washed twice in PBS with 2% FBS and were an-
alyzed on a FACS Aria II (BD Biosciences) high-speed cell sorter using
the 647 nm excitation and 100 μm nozzle. Unstained controls were
also analyzed as negative control to exclude data from non-specific
fluorescence.
DNA fingerprinting
STR analysis was performed by using AuthentiFiler PCR Amplifica-
tion Kit (Thermo Fisher Scientific).
Mycoplasma test
iPSCs were confirmed to be mycoplasma-negative using the
MycoAlert kit (Lonza, Basel, Switzerland) in accordance with the
manufacturer's instructions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.07.028.
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Table 2
Summary of antibodies and primers.
Antibodies used for immunocytochemistry/flow cytometry
Antibody Dilution Company Cat# and RRID
Pluripotency markers Rabbit anti-NANOG 1:500 Cosmo Bio Co
Cat# RCAB0003P,
RRID: AB_1962353
Pluripotency markers Mouse anti-SSEA-4 1:1000 Millipore
Cat# MAB4304,
RRID: AB_177629
Ectoderm differentiation markers Mouse anti-βIII-tubulin 1:500 Millipore
Cat# CBL412X,
RRID: AB_1977541
Mesoderm differentiation markers Mouse anti-αSMA 1:100 DAKO
Cat# M0851,
RRID: AB_2223500
Endoderm differentiation markers Goat anti-SOX17 1:300 R and D Systems
Cat# AF1924,
RRID: AB_355060
Secondary antibodies Donkey anti-Goat IgG Alexa Fluor 488 1:1000 Thermo Fisher Scientific
Cat# A-11055,
RRID: AB_142672
Secondary antibodies Goat anti-Rabbit IgG Alexa Fluor 488 1:1000 Thermo Fisher Scientific
Cat# A-11034,
RRID: AB_2576217




Target Forward/Reverse primer (5′-3′)
Genotyping SLC20A2 Fw:GCTGAAGAGAAGAATCCCCAAAC
Rv:GGTGAACAGTGTGGGATGGAG
Fig. 1. Characterization of the iPSC line. (A) Established IBGC-iPSCs displayed a typical round-shaped colony. Immunocytochemical staining of iPSCs showed positive stainning of
pluripotency markers NANOG (green) and SSEA-4 (red). Scale bars: 200 μm. (B) Spontaneously differentiated cells after embryoid body formation showed positive staining for each
marker of three-germ layer: βIII-tubulin (red), alpha smooth muscle actin: αSMA (red), and SOX17 (green). Scale bars: 100 μm. (C) Karyotype analysis of patient iPSCs showed a
normal karyotype of 46 XY. (D) Sanger sequence of the SLC20A2 gene in iPSCs showed a heterozygous c.1848G N A (p.W616*) mutation. (E) FACS analysis with evaluation of SSEA-4
staining.
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